AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer Strategy at Virtual Investor Event

Reuters02-12 21:55

AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer <a href="https://laohu8.com/S/MSTR">Strategy</a> at Virtual Investor Event

AIM ImmunoTech Inc. (NYSE American: AIM) will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. The event will include a live video webcast featuring Tom Equels, Chief Executive Officer of AIM ImmunoTech, who will discuss the company’s clinical and regulatory strategy for its lead drug Ampligen, particularly its role in the ongoing DURIPANC clinical trial in collaboration with AstraZeneca. The trial combines Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer. The live webcast will be available on the Events page of the company's website (aimimmuno.com), with a replay accessible two hours after the live presentation for 90 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653233-en) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610614924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610614924","market":"nz","top_or_hot":-1,"title":"AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer Strategy at Virtual Investor Event","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> at Virtual Investor Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AIM\">AIM ImmunoTech Inc.</a> (NYSE American: AIM) will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. The event will include a live video webcast featuring Tom Equels, Chief Executive Officer of AIM ImmunoTech, who will discuss the company’s clinical and regulatory strategy for its lead drug Ampligen, particularly its role in the ongoing DURIPANC clinical trial in collaboration with AstraZeneca. The trial combines Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer. The live webcast will be available on the Events page of the company's website (aimimmuno.com), with a replay accessible two hours after the live presentation for 90 days.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AIMI\">AIM ImmunoTech Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653233-en) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer Strategy at Virtual Investor Event</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer Strategy at Virtual Investor Event\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> at Virtual Investor Event\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AIM\">AIM ImmunoTech Inc.</a> (NYSE American: AIM) will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. The event will include a live video webcast featuring Tom Equels, Chief Executive Officer of AIM ImmunoTech, who will discuss the company’s clinical and regulatory strategy for its lead drug Ampligen, particularly its role in the ongoing DURIPANC clinical trial in collaboration with AstraZeneca. The trial combines Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer. The live webcast will be available on the Events page of the company's website (aimimmuno.com), with a replay accessible two hours after the live presentation for 90 days.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/AIMI\">AIM ImmunoTech Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653233-en) on February 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0575583348.USD","symbol_name":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL86hYRf:1","article_id":"2610614924","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610614924","pubTimestamp":1770904512,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AIM ImmunoTech Inc.  will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. The event will include a live video webcast featuring Tom Equels, Chief Executive Officer of AIM ImmunoTech, who will discuss the company’s clinical and regulatory strategy for its lead drug Ampligen, particularly its role in the ongoing DURIPANC clinical trial in collaboration with AstraZeneca. The trial combines Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi  for the treatment of metastatic pancreatic cancer. The live webcast will be available on the Events page of the company's website , with a replay accessible two hours after the live presentation for 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0047473722.EUR":"HSBC GIF EUROPE VALUE \"PD\" (EUR) INC","LU0957799991.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"ZUH\" (USDHDG) ACC","LU0827474353.SGD":"Allianz Europe Equity Growth Cl AT Acc H2-SGD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU1104425308.USD":"BNP PARIBAS EUROPE GROWTH \"C\" (USD) ACC","LU1170363599.USD":"ALLIANZ EUROPE EQUITY GROWTH SELECT \"A\" (USDHDG) INC","LU1019632923.USD":"Blackrock European Equity Income A6 USD-H","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0823399737.USD":"BNP PARIBAS EUROPE EQUITY \"C\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","03165":"华夏欧优股对冲","LU0058720904.USD":"联博国际健康护理基金A","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","LU2279689827.SGD":"JPMorgan Investment Funds - Global Income Sustainable A (mth) SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","AIM":"AIM ImmunoTech Inc.","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","IE00BKPKM643.USD":"NEUBERGER BERMAN EUROPEAN SUSTAINABLE EQUITY \"A\" (USDHDG) ACC","AZN.UK":"阿斯利康制药","LU0960981461.USD":"BNP PARIBAS EUROPE GROWTH \"C\" (USDHDG) INC","NDAQ":"纳斯达克OMX交易所","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0757432116.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AE\" (USD) ACC","LU1301847155.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A4G\" (USD) INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0920783379.SGD":"Allianz Europe Equity Growth Select Cl AT Acc H2-SGD","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","BK4585":"ETF&股票定投概念","LU0784385170.HKD":"BGF GLOBAL MULTI ASSET INCOME \"A6\" (HKDHGD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1880407132.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) ACC","LU2293690082.USD":"SCHRODER ISF EUROPEAN SUSTAINABLE EQUITY \"A\" (USD) INC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC"},"translate_title":"AIM ImmunoTech首席执行官将在虚拟投资者活动中介绍Ampligen胰腺癌战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"NDAQ":0.9,"AIM":0.9,"AZN.UK":0.9},"content_text":"AIM ImmunoTech CEO to Present Ampligen Pancreatic Cancer Strategy at Virtual Investor Event\n    \n\nAIM ImmunoTech Inc. (NYSE American: AIM) will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. The event will include a live video webcast featuring Tom Equels, Chief Executive Officer of AIM ImmunoTech, who will discuss the company’s clinical and regulatory strategy for its lead drug Ampligen, particularly its role in the ongoing DURIPANC clinical trial in collaboration with AstraZeneca. The trial combines Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) for the treatment of metastatic pancreatic cancer. The live webcast will be available on the Events page of the company's website (aimimmuno.com), with a replay accessible two hours after the live presentation for 90 days.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653233-en) on February 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610614924","isCrawlerRequest":true}